Medicamen Biotech Ltd

For the second consecutive session, Medicamen Biotech Ltd has seen its share price slide further, hitting a fresh 52-week low of Rs 225 on 30 Mar 2026. This decline extends a recent losing streak that has erased nearly 10% of its value over two days, underscoring persistent selling pressure amid a challenging market backdrop.

A sharp decline in Medicamen Biotech Ltd has pushed the stock to a fresh 52-week low of Rs 234.35 on 27 Mar 2026, marking a significant 47.95% drop over the past year. This downturn comes amid broader market weakness and persistent underperformance relative to benchmarks and peers.

For the fifth consecutive session, Medicamen Biotech Ltd has closed lower, hitting a fresh 52-week low of Rs 243.25 on 23 Mar 2026. This decline comes amid a broader sector downturn but marks a significant underperformance relative to the market and peers.

For the fifth consecutive session, Medicamen Biotech Ltd has closed lower, slipping to a fresh 52-week low of Rs 243.25 on 23 Mar 2026. This decline comes amid a broader sector weakness but is notably sharper than the overall Pharmaceuticals & Biotechnology sector's fall of 3.16% today.

Medicamen Biotech Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 14 February 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 23 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

For the second consecutive session, Medicamen Biotech Ltd has seen its share price decline, hitting a fresh 52-week low of Rs 260.3 on 20 Mar 2026. This latest drop extends the stock’s downward trajectory, which has now resulted in a 3.93% loss over the past two days, underperforming its sector by 1.51% today.

Medicamen Biotech Ltd’s shares declined to a fresh 52-week low of Rs.262.5 on 19 Mar 2026, marking a significant drop amid broader market weakness and company-specific performance concerns. The stock underperformed its sector and key benchmarks, reflecting ongoing challenges in sustaining growth momentum.

Medicamen Biotech Ltd has reached a new 52-week low of Rs.263.65 today, marking a significant decline in its stock price amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on its financial performance and valuation metrics.

Medicamen Biotech Ltd’s shares declined to a fresh 52-week low of Rs.270 on 13 Mar 2026, marking a significant downturn amid broader market weakness and persistent underperformance relative to its sector and benchmark indices.

Medicamen Biotech Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating despite ongoing challenges in the Pharmaceuticals & Biotechnology sector. The company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios, alongside other key financial metrics, reveal a complex picture of valuation attractiveness contrasted with operational and market headwinds.

Medicamen Biotech Ltd’s shares declined to a fresh 52-week low of Rs.275.95 on 12 Mar 2026, marking a significant downturn amid broader market weakness and company-specific performance concerns. The stock has underperformed its sector and key benchmarks, reflecting ongoing pressures in the Pharmaceuticals & Biotechnology space.

Medicamen Biotech Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 14 February 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are based on the company’s current position as of 10 March 2026, providing investors with the latest comprehensive view of the stock’s performance and prospects.

Medicamen Biotech Ltd’s share price declined sharply to a new 52-week low of Rs.277.05 today, marking a significant downturn amid broader market fluctuations. The stock opened with an 8% gap down and has now fallen for two consecutive sessions, underperforming its sector and the broader market indices.

Medicamen Biotech Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 26 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Medicamen Biotech Ltd’s shares declined sharply to a new 52-week low of Rs.292.05 on 25 Feb 2026, marking a significant drop amid broader market gains. The stock underperformed its sector and key benchmarks, reflecting ongoing concerns about its financial performance and valuation metrics.

Medicamen Biotech Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 15 February 2026, providing investors with the latest insights into the company’s performance and outlook.